US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
2024 full-year revenue guidance raised by US$ 2 billion
Subscribe To Our Newsletter & Stay Updated
